Skip to content
GSK Jumps, Astrazeneca Up episode artwork

Sep 14, 2026 2 min

GSK Jumps, Astrazeneca Up

from Stock Movers Hosted by iHeartPodcasts

Today's biggest winners and losers in the stock market. On this episode of Stock Movers: - GSK announced that its Jideytro (zidesamtinib) achieved a 94% objective response rate in TKI-naïve ROS1-positive non-small cell lung cancer patients in the registrational phase I/II ARROS-1 trial, with no placebo comparator. - AstraZeneca’s breast-cancer pill trial failure could cut several billion dollars from the drug’s potential sales, according to analysts.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

GSK Jumps, Astrazeneca Up

0:00 2:53

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Stock Movers?

This episode is 2 minutes long.

When was this Stock Movers episode published?

This episode was published on September 14, 2026.

Can I download this Stock Movers episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.